Serum Lipid Profile in Chronic Kidney Disease Patients on Haemodialysis

Balode, Ashwini A.; Khan, Zahidullah

doi:10.15373/2249555x/aug2013/7

Cited by 8 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 It is more likely that patients with CKD will die because of CVD than develop ESRD and have the need for renal replacement therapy. 3,4 Compared with the general population, patients with CKD…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 50% of ESRD patients die because of CVD, and cardiovascular mortality is 30 times higher in dialysis patients. 4,10,14 HD patients have moderately increased apoB and significantly increased apoC-III. Triglyceride-rich apoB containing lipoproteins (VLDL and IDL) are elevated because of decreased activities of lipoprotein lipase and hepatic lipase, resulting in hypertriglyceridemia.…”

mentioning

confidence: 95%

“…5 These risk factors can be both traditional ones such as age, male gender, diabetes, obesity, hypertension, and dyslipidemia and non-traditional uremia-related risk factors such as anemia, hyperhomocysteinemia, mineral bone disease-CKD with hyperparathyroidism, oxidative stress, hypoalbuminemia, and chronic inflammation. 3,4 In the general population, high total cholesterol (TC), high low-density lipoprotein (LDL) cholesterol, high triglyceride, and low high-density lipoprotein (HDL) cholesterol are all well-established risk factors for CVD development. However, CKD, with both dialysis and transplantation, is associated with specific qualitative and quantitative lipid abnormalities, resulting in specific dyslipidemia (Table 1).…”

mentioning

confidence: 99%

“…Along with CKD progression, metabolic abnormalities may progress further, contributing to atherosclerotic changes and adversely affecting renal function. 1,4,7 According to the current evidence, lipid-lowering medications are effective in reducing CVD mortality and morbidity in the general population. Recent studies suggest that these medications may have the same beneficial effect in both CKD and the transplant population.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Dyslipidemia in patients with chronic kidney disease: etiology and management

Mikolašević¹,

Žutelija²,

Mavrinac³

et al. 2017

IJNRD

197

149

View full text Add to dashboard Cite

Abstract:Patients with chronic kidney disease (CKD), including those with end-stage renal disease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is an important risk factor for CVD development. Specific quantitative and qualitative changes are seen at different stages of renal impairment and are associated with the degree of glomerular filtration rate declining. Patients with non-dialysis-dependent CKD have low high-density lipoproteins (HDL), normal or low total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, increased triglycerides as well as increased apolipoprotein B (apoB), lipoprotein(a) (Lp (a)), intermediate-and very-low-density lipoprotein (IDL, VLDL; "remnant particles"), and small dense LDL particles. In patients with nephrotic syndrome lipid profile is more atherogenic with increased TC, LDL, and triglycerides. Lipid profile in hemodialysis (HD) patients is usually similar to that in non-dialysis-dependent CKD patients. Patients on peritoneal dialysis (PD) have more altered dyslipidemia compared to HD patients, which is more atherogenic in nature. These differences may be attributed to PD per se but may also be associated with the selection of dialytic modality. In renal transplant recipients, TC, LDL, VLDL, and triglycerides are elevated, whereas HDL is significantly reduced. Many factors can influence post-transplant dyslipidemia including immunosuppressive agents. This patient population is obviously at high risk; hence, prompt diagnosis and management are required to improve their clinical outcomes. Various studies have shown statins to be effective in the cardiovascular risk reduction in patients with mild-to-moderate CKD as well as in renal transplant recipients. However, according to recent clinical randomized controlled trials (4D, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Dialysis: an Assessment of Survival and Cardiovascular Events, and Study of Heart and Renal protection), these beneficial effects are uncertain in dialyzed patients. Therefore, further research for the most suitable treatment options is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 95%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Dyslipidemia in patients with chronic kidney disease: etiology and management

Mikolašević¹,

Žutelija²,

Mavrinac³

et al. 2017

IJNRD

197

149

View full text Add to dashboard Cite

show abstract

“…От 40 до 50% пациентов с терминальной ХБП имеют уровень ТГ>2,26 ммоль/л, ЛПНП>3,4 ммоль/л. Липопротеиновый профиль при ХБП характеризуется количественными и качественными отклонениями от нормы, которые еще больше усугубляются по мере снижения СКФ, достигая максимальной выраженности у пациентов на терминальной стадии болезни почек [5][6][7][8]. Для большинства пациентов с ХБП 3-5 стадии характерна смешанная дислипидемия, а липидной профиль характеризуется высокой атерогенностью с изменениями всех фракций липопротеинов.…”

Section: материал и методыunclassified

Dyslipidemia in Kidney Receiver

Мартиросян

Космачева

2019

Innovative Medicine of Kuban

View full text Add to dashboard Cite

Background Kidney transplantation is the gold standard of treatment in patients with a terminal renal failure. Nevertheless, the main reason for death of recipients, loss of the renal allograft is cardiovascular disease, and disorder of lipid profile remains one of the most significant risk factors and progressing of cardiovascular pathology. Aim We estimated dyslipidemia dynamics before and at various terms after kidney transplantation and we tried to reveal interrelation of disorder of lipid metabolism with renal transplant functioning. Material and Methods The retrospective observational research of the cohort in a uniform group of lipid profile dynamics observation in terms before kidney transplantation and in 6, 12 and 36 months of two hundred liver recipients at the age of 40.18±10.33 years has been conducted. Among those there was 41.5% female patients and 58.5% male patients. The statistical analysis was carried out by means of STATISTICA 10.0 program. The critical significance value while checking statistical hypotheses in this research was accepted equal 0.05. The method of multifactorial logistic regression was applied to search factors associated with a dyslipidemia. Results Level of the general cholesterol before transplantation was 4.34±1.21 mmol/l, in comparison with an initial indicator of the general cholesterol increase in dynamics in 12 and 36 months was 17.5% (р = 0.02), 22.9% (р = 0.03), respectively. The LDL level in the studied cohort of recipients was around 2.36±1.21 mmol, and in 6 months it increased by 12.3% (р = 0.02), in a year for 5.9% (р = 0.21) and 36 months later differed from initial on 14.8 (р = 0.01). In three years after transplantation period LPVP decreased by 12.3% (р = 0.01). In comparison with initial level before transplantation they increased on 8,9% (р = 0,03) и 16,7% (р =0,01) in 12 and 36 months, respectively. The factors associated with dyslipidemia is the age - 1.21-1.7 (р<0.02), diabetes – 1.1-1.5 (р<0.03), the speed of glomerular filtration (kg/sq.m) - 1.23-1.32 (р<0.02), proteinuria (g/l)-1.55-2.1 (р<0.001), the left ventricle myocardium mass index (kg/sq.m)-1.23-1.55 (р <0.03), hemoglobin (g/l)-1.1-1.23 (р<0.04), systolic arterial blood pressure-1.2-2.1 (р<0.001), diastolic arterial blood pressure – 1.1-2.2 (р<0.002). The negative correlational interrelation between the level of cholesterol and survival of the renal allograft, estimated on the speed of glomerular filtration was revealed (р = 0.003). Level of the general cholesterol was a significant independent predictor for survival and functioning of the renal allotransplantat in 3 years after transplantation. Conclusion The progressing disorder of a lipid profile in the long-term post-transplantation period was revealed, dyslipidemia is a significant modified predictor of successful kidney transplantation.

show abstract

Development of a risk prediction score and equation for chronic kidney disease: a retrospective cohort study

Kawasoe

Kubozono

Salim

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a risk factor for end-stage renal disease and contributes to increased risk of cardiovascular disease morbidity and mortality. We aimed to develop a risk prediction score and equation for future CKD using health checkup data. This study included 58,423 Japanese participants aged 30–69 years, who were randomly assigned to derivation and validation cohorts at a ratio of 2:1. The predictors were anthropometric indices, life style, and blood sampling data. In derivation cohort, we performed multivariable logistic regression analysis and obtained the standardized beta coefficient of each factor that was significantly associated with new-onset CKD and assigned scores to each factor. We created a score and an equation to predict CKD after 5 years and applied them to validation cohort to assess their reproducibility. The risk score ranged 0–16, consisting of age, sex, hypertension, dyslipidemia, diabetes, hyperuricemia, and estimated glomerular filtration rate (eGFR), with area under the curve (AUC) of 0.78 for the derivation cohort and 0.79 for the validation cohort. The CKD incidence gradually and constantly increased as the score increased from ≤ 6 to ≥ 14. The equation consisted of the seven indices described above, with AUC of 0.88 for the derivation cohort and 0.89 for the validation cohort. We developed a risk score and equation to predict CKD incidence after 5 years in Japanese population under 70 years of age. These models had reasonably high predictivity, and their reproducibility was confirmed through internal validation.

show abstract

Serum Lipid Profile in Chronic Kidney Disease Patients on Haemodialysis

Cited by 8 publications

References 9 publications

Dyslipidemia in patients with chronic kidney disease: etiology and management

Dyslipidemia in patients with chronic kidney disease: etiology and management

Dyslipidemia in Kidney Receiver

Development of a risk prediction score and equation for chronic kidney disease: a retrospective cohort study

Contact Info

Product

Resources

About